Your browser doesn't support javascript.
loading
Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States.
Ganatra, Sarju; Dani, Sourbha S; Kumar, Ashish; Khan, Safi U; Wadhera, Rishi; Neilan, Tomas G; Thavendiranathan, Paaladinesh; Barac, Ana; Hermann, Joerg; Leja, Monika; Deswal, Anita; Fradley, Michael; Liu, Jennifer E; Sadler, Diego; Asnani, Aarti; Baldassarre, Lauren A; Gupta, Dipti; Yang, Eric; Guha, Avirup; Brown, Sherry-Ann; Stevens, Jennifer; Hayek, Salim S; Porter, Charles; Kalra, Ankur; Baron, Suzanne J; Ky, Bonnie; Virani, Salim S; Kazi, Dhruv; Nasir, Khurram; Nohria, Anju.
Afiliación
  • Ganatra S; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
  • Dani SS; Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
  • Kumar A; Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
  • Khan SU; Department of Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA.
  • Wadhera R; Department of Cardiovascular Medicine, Houston Methodist, Houston, Texas, USA.
  • Neilan TG; Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Thavendiranathan P; Cardiovascular Imaging Research Center and Cardio-Oncology Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Barac A; Ted Rogers Program in Cardiotoxicity Prevention, Division of Cardiology and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Hermann J; Cardio-Oncology Program, Department of Cardiology, MedStar Washington Hospital Center, MedStar Heart and Vascular Institute, Washington, District of Columbia, USA.
  • Leja M; Cardio-Oncology Program, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Deswal A; Cardio-Oncology Program, Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Fradley M; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
  • Liu JE; Cardio-Oncology Translational Center of Excellence, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Sadler D; Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Asnani A; Cardio-Oncology Program, Department of Cardiovascular Medicine, Cleveland Clinic Florida, Weston, Florida, USA.
  • Baldassarre LA; Cardio-Oncology Program, Department of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Gupta D; Cardio-Oncology Program, Department of Cardiovascular Medicine, Yale New Haven Hospital, Yale University, New Haven, Connecticut, USA.
  • Yang E; Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Guha A; Cardio-Oncology Program, Department of Cardiovascular Medicine, University of California-Los Angeles, Los Angeles, California, USA.
  • Brown SA; Cardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
  • Stevens J; Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Hayek SS; Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Porter C; Cardio-Oncology Program, Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Kalra A; Cardio-Oncology Program, Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, Missouri, USA.
  • Baron SJ; Department of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA.
  • Ky B; Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
  • Virani SS; Cardio-Oncology Translational Center of Excellence, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Kazi D; Health Policy and Quality Program, Michael E. DeBakey VA Medical Center, Health Services Research and Development Center of Excellence and Section of Health Services Research, Baylor College of Medicine, Houston, Texas, USA.
  • Nasir K; Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Nohria A; Department of Cardiovascular Medicine, Houston Methodist, Houston, Texas, USA.
JACC CardioOncol ; 4(3): 326-337, 2022 Sep.
Article en En | MEDLINE | ID: mdl-36213357
ABSTRACT

Background:

Racial and social disparities exist in outcomes related to cancer and cardiovascular disease (CVD).

Objectives:

The aim of this cross-sectional study was to study the impact of social vulnerability on mortality attributed to comorbid cancer and CVD.

Methods:

The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database (2015-2019) was used to obtain county-level mortality data attributed to cancer, CVD, and comorbid cancer and CVD. County-level social vulnerability index (SVI) data (2014-2018) were obtained from the CDC's Agency for Toxic Substances and Disease Registry. SVI percentiles were generated for each county and aggregated to form SVI quartiles. Age-adjusted mortality rates (AAMRs) were estimated and compared across SVI quartiles to assess the impact of social vulnerability on mortality related to cancer, CVD, and comorbid cancer and CVD.

Results:

The AAMR for comorbid cancer and CVD was 47.75 (95% CI 47.66-47.85) per 100,000 person-years, with higher mortality in counties with greater social vulnerability. AAMRs for cancer and CVD were also significantly greater in counties with the highest SVIs. However, the proportional increase in mortality between the highest and lowest SVI counties was greater for comorbid cancer and CVD than for either cancer or CVD alone. Adults <45 years of age, women, Asian and Pacific Islanders, and Hispanics had the highest relative increase in comorbid cancer and CVD mortality between the fourth and first SVI quartiles, without significant urban-rural differences.

Conclusions:

Comorbid cancer and CVD mortality increased in counties with higher social vulnerability. Improved education, resource allocation, and targeted public health interventions are needed to address inequities in cardio-oncology.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: JACC CardioOncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: JACC CardioOncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos